Active Biotech to Present at the Rodman & Renshaw 12th Annual Healthcare Conference

Lund,  Sweden, September 9, 2010 -  Active Biotech (NASDAQ  OMX Nordic: ACTI) is
scheduled  to present at the Rodman  & Renshaw 12th Annual Healthcare Conference
on  Tuesday, September  14 at the  New York  Palace Hotel  in New York City, US.
During  the  presentation,  an  update  regarding  Active  Biotech's development
programs will be provided.

The  presentation will include projects in  or entering Phase III; laquinimod, a
novel  oral  immunomodulatory  drug  for  the  treatment  of multiple sclerosis,
licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project TASQ
and  ANYARA, Active  Biotech's novel  concept for  tumor therapy  in a Phase III
study  for renal cell  cancer. Also, the  project 57-57 and the pre-clinical ISI
project will be presented.

The  audio and slide presentation will be webcasted live and can be accessed via
the  Active Biotech web site. To access the live and replay presentations please
go to -

The presentation will take place on September 14, at 2:25 pm US Eastern Daylight
Time / 20:25 Central European Summer Time.

About Active Biotech

Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases  and cancer. Projects  in or entering
pivotal  phase are laquinimod, an orally administered small molecule with unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer as well as ANYARA for use in cancer targeted therapy, primarily
of  renal cell cancer.  In addition, laquinimod  is in Phase  II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visit www.activebiotech.comfor more information.

Active  Biotech  is  required  under  the  Securities  Markets  Act  to make the
information  in this  press release  public. The  information was  submitted for
publication at 08:30 a.m. CEST on September 9, 2010.


Active Biotech AB
Göran Forsberg, VP Investor Relations & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00


Active Biotech to present at the Rodman & Renshaw 12th Annual Healthcare Conference:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE